Ascendis Pharma A/S is a pharmaceutical company based in Denmark, with a medium risk rating score of 27.8. Specializing in biopharmaceuticals, Ascendis Pharma develops prodrug therapies using Transcon technology to target large markets with unmet medical needs. Their product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and more. Operating in North America, China, and Europe, Ascendis Pharma derives the majority of its revenue from North America. The company focuses on ESG principles to ensure sustainability and governance in its operations.